Literature DB >> 12649177

A novel gene, MSI2, encoding a putative RNA-binding protein is recurrently rearranged at disease progression of chronic myeloid leukemia and forms a fusion gene with HOXA9 as a result of the cryptic t(7;17)(p15;q23).

Aikaterini Barbouti1, Mattias Höglund, Bertil Johansson, Carin Lassen, Per-Gunnar Nilsson, Anne Hagemeijer, Felix Mitelman, Thoas Fioretos.   

Abstract

The pathogenetic role of the P210 BCR/ABL1 fusion gene in the chronic phase of chronic myeloid leukemia (CML) has been well established.In contrast, the genetic mechanisms underlying the disease progression into the accelerated phase (AP) and the final blast crisis (BC) remain poorly understood. We have previously identified (A. Barbouti et al., Genes Chromosomes Cancer, 35: 127-137, 2002) two cryptic balanced translocations, t(7;17)(p15;q23) and t(7;17)(q32-34;q23), in CML AP/BC using multicolor fluorescence in situ hybridization. In this study, we show that a novel gene in 17q23, Musashi-2 (MSI2), encoding a putative RNA-binding protein, is rearranged in both cases and that a MSI2/HOXA9 fusion gene is formed in the case with the 7p15 breakpoint. The identified in-frame MSI2/HOXA9 fusion transcript retains both of the RNA recognition motif domains of MSI2, which is fused to the homeobox domain of HOXA9, and is likely to play an important role in the disease progression of CML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12649177

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  36 in total

1.  Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program.

Authors:  Sun-Mi Park; Mithat Gönen; Ly Vu; Gerard Minuesa; Patrick Tivnan; Trevor S Barlowe; James Taggart; Yuheng Lu; Raquel P Deering; Nir Hacohen; Maria E Figueroa; Elisabeth Paietta; Hugo F Fernandez; Martin S Tallman; Ari Melnick; Ross Levine; Christina Leslie; Christopher J Lengner; Michael G Kharas
Journal:  J Clin Invest       Date:  2015-02-09       Impact factor: 14.808

Review 2.  Stem Cells, Cancer, and MUSASHI in Blood and Guts.

Authors:  Michael G Kharas; Christopher J Lengner
Journal:  Trends Cancer       Date:  2017-04-08

Review 3.  Musashi RNA-Binding Proteins as Cancer Drivers and Novel Therapeutic Targets.

Authors:  Alexander E Kudinov; John Karanicolas; Erica A Golemis; Yanis Boumber
Journal:  Clin Cancer Res       Date:  2017-01-31       Impact factor: 12.531

4.  The Human MSI2 Gene is Associated with Schizophrenia in the Chinese Han Population.

Authors:  Zhilin Luan; Tianlan Lu; Yanyan Ruan; Weihua Yue; Dai Zhang
Journal:  Neurosci Bull       Date:  2016-04-08       Impact factor: 5.203

5.  Musashi-2 promotes hepatitis Bvirus related hepatocellular carcinoma progression via the Wnt/β-catenin pathway.

Authors:  Ming-Hai Wang; Shi-Yong Qin; Shu-Guang Zhang; Guang-Xin Li; Zhen-Hai Yu; Kun Wang; Bin Wang; Mu-Jian Teng; Zhi-Hai Peng
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  Identify the signature genes for diagnose of uveal melanoma by weight gene co-expression network analysis.

Authors:  Kai Shi; Zhi-Tong Bing; Gui-Qun Cao; Ling Guo; Ya-Na Cao; Hai-Ou Jiang; Mei-Xia Zhang
Journal:  Int J Ophthalmol       Date:  2015-04-18       Impact factor: 1.779

7.  Musashi-2 promotes migration and invasion in bladder cancer via activation of the JAK2/STAT3 pathway.

Authors:  Chenlu Yang; Weijing Zhang; Longwang Wang; Gallina Kazobinka; Xiaomin Han; Bin Li; Teng Hou
Journal:  Lab Invest       Date:  2016-06-20       Impact factor: 5.662

8.  The Novel KLF4/MSI2 Signaling Pathway Regulates Growth and Metastasis of Pancreatic Cancer.

Authors:  Kun Guo; Jiujie Cui; Ming Quan; Dacheng Xie; Zhiliang Jia; Daoyan Wei; Liang Wang; Yong Gao; Qingyong Ma; Keping Xie
Journal:  Clin Cancer Res       Date:  2016-07-22       Impact factor: 12.531

9.  Zebrafish stem/progenitor factor msi2b exhibits two phases of activity mediated by different splice variants.

Authors:  Tatiana Hochgreb-Hägele; Daniel E S Koo; Neha M Das; Marianne E Bronner
Journal:  Stem Cells       Date:  2014-02       Impact factor: 6.277

10.  Downregulation of Prdm16 mRNA is a specific antileukemic mechanism during HOXB4-mediated HSC expansion in vivo.

Authors:  Hui Yu; Geoffrey Neale; Hui Zhang; Han M Lee; Zhijun Ma; Sheng Zhou; Bernard G Forget; Brian P Sorrentino
Journal:  Blood       Date:  2014-07-31       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.